JP2023539591A5 - - Google Patents
Info
- Publication number
- JP2023539591A5 JP2023539591A5 JP2023513346A JP2023513346A JP2023539591A5 JP 2023539591 A5 JP2023539591 A5 JP 2023539591A5 JP 2023513346 A JP2023513346 A JP 2023513346A JP 2023513346 A JP2023513346 A JP 2023513346A JP 2023539591 A5 JP2023539591 A5 JP 2023539591A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- heavy chain
- light chain
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026081867A JP2026121476A (ja) | 2020-08-25 | 2026-05-14 | Ｂｃｍａキメラ抗原受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063069784P | 2020-08-25 | 2020-08-25 | |
| US63/069,784 | 2020-08-25 | ||
| PCT/US2021/047290 WO2022046730A2 (en) | 2020-08-25 | 2021-08-24 | Bcma chimeric antigen receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026081867A Division JP2026121476A (ja) | 2020-08-25 | 2026-05-14 | Ｂｃｍａキメラ抗原受容体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023539591A JP2023539591A (ja) | 2023-09-15 |
| JP2023539591A5 true JP2023539591A5 (enExample) | 2024-08-30 |
Family
ID=80353966
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513346A Ceased JP2023539591A (ja) | 2020-08-25 | 2021-08-24 | Ｂｃｍａキメラ抗原受容体 |
| JP2026081867A Pending JP2026121476A (ja) | 2020-08-25 | 2026-05-14 | Ｂｃｍａキメラ抗原受容体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026081867A Pending JP2026121476A (ja) | 2020-08-25 | 2026-05-14 | Ｂｃｍａキメラ抗原受容体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230310604A1 (enExample) |
| EP (1) | EP4204457A4 (enExample) |
| JP (2) | JP2023539591A (enExample) |
| KR (1) | KR20230053650A (enExample) |
| CN (1) | CN116348496A (enExample) |
| AU (1) | AU2021330958A1 (enExample) |
| BR (1) | BR112023003337A2 (enExample) |
| CA (1) | CA3191855A1 (enExample) |
| IL (1) | IL300612A (enExample) |
| MX (1) | MX2023002373A (enExample) |
| WO (1) | WO2022046730A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4370541A1 (en) | 2021-07-14 | 2024-05-22 | 2seventy bio, Inc. | Engineered t cell receptors fused to binding domains from antibodies |
| AU2023248532A1 (en) | 2022-04-08 | 2024-11-21 | Regeneron Pharmaceuticals, Inc. | Multipartite receptor and signaling complexes |
| WO2024207008A2 (en) * | 2023-03-30 | 2024-10-03 | Kelonia Therapeutics, Inc. | In vivo lentivirus animal models |
| WO2025171388A1 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens with modified domains and related methods and uses |
| WO2025171383A2 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens and related methods and uses |
| WO2026006767A1 (en) | 2024-06-28 | 2026-01-02 | Dispatch Biotherapeutics, Inc. | Tethered il-9/il-9r and related engineered cells and methods |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040071694A1 (en) * | 2002-10-14 | 2004-04-15 | Devries Peter J. | Erythropoietin receptor binding antibodies |
| EP3172231B1 (en) * | 2014-07-24 | 2021-05-05 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
| SG11201900885VA (en) * | 2016-08-01 | 2019-02-27 | Novartis Ag | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
| IL279367B2 (en) * | 2018-06-13 | 2026-05-01 | Novartis Ag | BCMA chimeric antigen receptors and their uses |
| EP4352232A4 (en) * | 2021-06-09 | 2025-05-21 | Serotiny, Inc. | Synthetic receptor for conditional activation of immune cells |
-
2021
- 2021-08-24 US US18/023,232 patent/US20230310604A1/en active Pending
- 2021-08-24 WO PCT/US2021/047290 patent/WO2022046730A2/en not_active Ceased
- 2021-08-24 AU AU2021330958A patent/AU2021330958A1/en active Pending
- 2021-08-24 CN CN202180070491.5A patent/CN116348496A/zh active Pending
- 2021-08-24 IL IL300612A patent/IL300612A/en unknown
- 2021-08-24 CA CA3191855A patent/CA3191855A1/en active Pending
- 2021-08-24 BR BR112023003337A patent/BR112023003337A2/pt unknown
- 2021-08-24 MX MX2023002373A patent/MX2023002373A/es unknown
- 2021-08-24 KR KR1020237009062A patent/KR20230053650A/ko active Pending
- 2021-08-24 EP EP21862543.2A patent/EP4204457A4/en active Pending
- 2021-08-24 JP JP2023513346A patent/JP2023539591A/ja not_active Ceased
-
2026
- 2026-05-14 JP JP2026081867A patent/JP2026121476A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11932873B2 (en) | Reducing immune tolerance induced by PD-L1 | |
| JP7741732B2 (ja) | Ｂｃｍａを標的とする操作された免疫細胞及びその使用 | |
| JP2018526028A5 (enExample) | ||
| JP2017522882A5 (enExample) | ||
| JP2017538710A5 (enExample) | ||
| CN115386010B (zh) | 靶向gprc5d的嵌合抗原受体及其用途 | |
| EP3964238A1 (en) | Bcma-targeting engineered immune cell and use thereof | |
| JP2022537159A5 (enExample) | ||
| JP2020525536A5 (enExample) | ||
| RU2017106025A (ru) | Химерные антигенные рецепторы к bcma | |
| EP4273175A1 (en) | Novel chimeric antigen receptor and use thereof | |
| JP2021505137A5 (enExample) | ||
| US20240123068A1 (en) | Cd19 binders, car-t constructs comprising the same, and methods of using the same | |
| JP2021532742A5 (enExample) | ||
| CN114391021A (zh) | TGF-β受体和使用方法 | |
| JP2025504398A5 (enExample) | ||
| WO2023131063A1 (zh) | 特异性结合msln的嵌合抗原受体及其应用 | |
| JP2024513713A5 (enExample) | ||
| HK40110123A (en) | Engineered immune cell targeting bcma and use thereof | |
| NZ728555B2 (en) | Bcma chimeric antigen receptors | |
| HK40062446B (en) | Engineered immune cell targeting bcma and use thereof | |
| HK1228783A1 (en) | Reducing immune tolerance induced by pd l1 | |
| HK1228783B (en) | Reducing immune tolerance induced by pd l1 |